Cargando...
PARP inhibition — not all gene mutations are created equal
Preliminary results from TRITON2 demonstrate efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in ~50% of patients with metastatic castration-resistant prostate cancer and inactivation of BRCA1/BRCA2. However, those with ATM and CDK12 mutations do not seem to benefit. An improve...
Guardado en:
| Publicado en: | Nat Rev Urol |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7959484/ https://ncbi.nlm.nih.gov/pubmed/30498248 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41585-018-0129-3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|